Maddi Hebebrand

Cory Simpson, MD, PhD, assistant professor of dermatology at the University of Washington, spoke to the need for more treatment options in genetic skin conditions and the possibility of drug repurposing.

Virginia Sybert, MD, clinical professor of medical genetics at the University of Washington, discussed what dermatologists should know about molecular testing in clinical practice.

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, said Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital.

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) in the management of chronic spontaneous urticaria (CSU), a condition with limited therapeutic options over the past decade.

Researchers found patients reporting greater disease burden and lower health-related quality of life (HRQoL) are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

A poster from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conference held in Chicago, Illinois presented results of a clinical trial for patients with alopecia areata (AA). The trial used rilecitinib and showed promising results in patients with AA after most patients achieved significant hair regrowth following 15 months of treatment.